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Abstract: Gleason score (GS) 8–10 is associated with adverse outcomes in prostate cancer (PCa).
However, biopsy GS (bGS) may be upgraded or downgraded post-radical prostatectomy (RP).
We aimed to investigate predictive factors and oncologic outcomes of downgrade to pathologic
GS (pGS) 6–7 after RP in PCa patients with bGSs 8–10. We retrospectively reviewed clinical
data of patients with bGS ≥ 8 undergoing RP. pGS downgrade was defined as a pGS ≤ 7 from
bGS ≥ 8 post-RP. Univariate and multivariate cox regression analysis, logistic regression analysis,
and Kaplan–Meier curves were used to analyze pGS downgrade and biochemical recurrence
(BCR). Of 860 patients, 623 and 237 had bGS 8 and bGS ≥ 9, respectively. Post-RP, 332 patients
were downgraded to pGS ≤ 7; of these, 284 and 48 had bGS 8 and bGS ≥ 9, respectively.
Prostate-specific antigen (PSA) levels; clinical stage; and adverse pathologic features such as
extracapsular extension, seminal vesicle invasion and positive surgical margin were significantly
different between patients with pGS ≤ 7 and pGS ≥ 8. Furthermore, bGS 8 (odds ratio (OR): 0.349,
p < 0.001), PSA level < 10 ng/mL (OR: 0.634, p = 0.004), and ≤cT3a (OR: 0.400, p < 0.001) were
identified as significant predictors of pGS downgrade. pGS downgrade was a significant positive
predictor of BCR following RP in patients with high bGS (vs. pGS 8, hazard radio (HR): 1.699,
p < 0.001; vs. pGS ≥ 9, HR: 1.765, p < 0.001). In addition, the 5-year BCR-free survival rate in patients
with pGS downgrade significantly differed from that in patients with bGS 8 and ≥ 9 (52.9% vs.
40.7%, p < 0.001). Among patients with bGS ≥ 8, those with bGS 8, PSA level < 10 ng/mL, and
≤cT3a may achieve pGS downgrade after RP. These patients may have fewer adverse pathologic
features and show a favorable prognosis; thus we suggest that active treatment is needed in these
patients. In addition, patients with high-grade bGS should be managed aggressively, even if they
show pGS downgrade.
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1. Introduction
Prostate cancer (PCa) is the most common type of newly diagnosed malignancy in men [1],
and it accounts for nearly 30% of all diagnosed male cancers [2]. Prostate-specific antigen (PSA)
measurements are widely used for PCa screening [3], and patients with elevated PSA levels undergo
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prostate biopsy for PCa diagnosis [4]. The Gleason score (GS) is the most commonly used grading
system for PCa. Gleason score at prostate biopsy (bGS) is one of the important parameters in the
evaluation, risk stratification, and selection of treatment modality in PCa patients [5,6]. Gleason score
was first introduced in 1974 by Donald Gleason and the Veterans Administration Cooperative Urologic
Research Group [7]. GS is continuously updated, and it was first revised in 2005 in the International
Society of Urological Pathology (ISUP) conference [8]. In the 2014 ISUP meeting, GS was further
revised, and a new 5-step Gleason grading system was introduced [9]. Despite these revisions, bGS ≥8
is still considered as high risk [10].
Biopsy and radical prostatectomy (RP) specimens can be discordant due to sampling errors and the
multifocal nature of PCa [11]. Several studies have already reported GS discrepancies between biopsy
and RP specimens [12,13]. A GS downgrade may also occur in patients with bGS ≥ 8 [14,15]. However,
few studies have predicted the discordance in GS between biopsy and RP specimens in patients with
bGS ≥ 8. We believe that predicting pathological downgrade (pGS ≤ 7) in patients with high-grade
prostate cancer may be beneficial in terms of oncologic outcomes and provide a reliable parameter
for defining the appropriate surgical treatment strategy. Therefore, this study aimed to investigate
prognostic factors of GS downgrade from biopsy to RP and to investigate oncologic outcomes after RP
in patients with bGS ≥ 8.
2. Materials and Methods
2.1. Patients and Study Design
We retrospectively retrieved the clinical and pathological data of 5438 PCa patients who
underwent RP at our institution between January 2005 and December 2016. Patients who had
undergone androgen deprivation therapy or external beam radiation therapy before RP and those
with incomplete pathological or follow-up data were excluded. All patients were diagnosed with PCa
via transrectal ultrasound (TRUS)-guided 12-core systematic needle biopsy.
The clinical characteristics of these patients including age, body mass index (BMI), preoperative
PSA levels, prostate volume measured via TRUS, clinical stage on multiparametric magnetic resonance
imaging (mpMRI), GS following prostate biopsy, and pathologic characteristics of RP specimens were
obtained through a review of medical records. The mpMRI images included standardized criteria for
Likert scoring of multiparametric sequences using a 3.0-T MRI system (Intera Achieva 3.0-T, Phillips
Medical System, Best, The Netherlands) [16]. All pathologic diagnoses were performed by expert
pathologists. Biopsy specimens obtained from other hospitals were reviewed by our pathologists.
The pathologists also reviewed the missing data in pathological reports of patients included in our
study and confirmed that there was no problem. The final identification was performed by the most
skilled pathologist to reduce possible errors between pathologists. We assigned GS according to the
2005 ISUP Modified Gleason System [8]. Gleason score at prostate biopsy was based on the core with
the highest GS. In case of multifocal disease, GS of the RP specimen was assigned based on the nodule
with the highest GS. Tertiary Gleason 5 patterns were assigned if the tertiary component comprised
<5% of the entire tumor [17]. Gleason score downgrade was defined as a downgrade to GS ≤ 7 in the
RP specimen from a bGS ≥ 8, which is classified as high-grade.
Finally, the tumor-node-metastasis (TNM) stage was determined according to the 8th edition of
the American Joint Committee on Cancer TNM staging system.
2.2. Follow-Up
Follow-up postoperative PSA test was performed monthly for the first 6 months, every 3 months
until the second year, and every 6 months thereafter. Biochemical recurrence (BCR) was defined as
any two consecutive increases in serum PSA ≥ 0.2 ng/mL following RP. Biochemical recurrence -free
survival was defined as the time from RP to BCR [18]. The follow-up period was calculated from the
time of RP to the date of the last known contact with the patient.
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2.3. Statistical Analysis
Univariate and multivariate Cox proportional hazards regression analyses were performed to
assess the association between baseline parameters and BCR-free survival. In addition, univariate and
multivariate logistic regression were performed to identify significant factors of pathologic downgrade.
The Kaplan–Meier method with log-rank tests were performed to estimate and compare oncologic
outcomes according to variations in GS from RP.
Significant variables from univariate analysis were included in multivariate analysis. All statistical
analyses were performed using SPSS Statistics software, version 23.0 (IBM, Armonk, NY, USA), and
p < 0.05 was considered statistically significant.
2.4. Ethics Approval and Informed Consent
The current research was approved by the Severance hospital institutional review board (approval
number 4-2018-1012). Informed consent from the participants was waived by the institutional review
board as the current study satisfied all of the following requirements for the waiver of informed
consent: the research involved no more than minimal risk to the participants (retrospective data
analysis of previously collected medical records).
3. Results
3.1. Patient and Disease Characteristics
Of the 5438 patients identified, 1126 had bGS ≥ 8. After excluding 266 patients who received
neoadjuvant therapy, 860 patients were finally included in the analysis. In total, 623 (72.4%) and
237 (27.6%) patients had bGS 8 and bGS ≥ 9, respectively. In the 860 specimens collected following
RP, the GS were 6, 7, 8, and ≥ 9 in 19 (2.2%), 313 (36.4%), 219 (25.5%), and 309 (35.9%) specimens,
respectively. Among 313 patients in GS 7, 130 (15.1%) had GS (3 + 4) and 183 (21.2%) had GS (4 + 3).
Therefore, 332 (38.6%) patients with pGS≤ 7 were followed after RP for pGS downgrade; the remaining
528 (61.4%) patients had pGS ≥ 8. Median follow-up period after RP was 51 months (interquartile
range, 26–78 months). In addition, patients with tertiary G5 patterns in the total RP specimen were
observed 15 in GS7 (3 + 4), 23 in GS7 (4 + 3) and 15 in GS8 (4 + 4).
When dividing the two groups (pGS ≤ 7 vs. pGS > 8) based on pathologic GS, there were
significant differences in preoperative PSA, PSA density, clinical stage, and bGS between the two
groups. Meanwhile, age, BMI, prostate volume, and follow-up duration did not differ significantly.
After RP, there were statistically significant differences in the pathological features (extracapsular
extension (ECE), seminal vesicle invasion (SVI), positive surgical margin (PSM), lymphovascular
invasion, and perineural invasion) between the two groups (Table 1).
Table 1. Baseline patient characteristics.
Variable
Total No_Downgrade Downgrade
P valueN = 860 N = 528 (61.4%) N = 332 (38.6%)
Median IQR Median IQR Median IQR
Age, year 67 62–71 67 62–71 66 62–70 0.578
BMI, kg/m2 24.09 22.38–25.97 24.05 22.32–25.90 24.22 22.50–26.00 0.608
PSA level, ng/mL 10.59 6.58–19.39 12.03 7.09–22.72 8.60 5.99–14.74 <0.001
PSA group, ng/mL N % N % N % <0.001
<10 445 51.7 236 44.7 209 63.0
≥10 415 48.3 292 55.3 123 37.0
PSA density, ng/mL2 0.33 0.20–0.62 0.38 0.22–0.75 0.28 0.18–0.50 <0.001
Prostate volume, mL 32.0 26.0–40.5 32.6 26.0–40.9 31.1 25.8–40.0 0.367
Clinical stage according to MRI N % N % N % <0.001
cT2 402 46.7 213 40.3 35 56.9
cT3a 292 34.0 176 33.3 116 34.9
≥cT3b 166 19.3 139 26.3 27 8.1
Gleason score according to Biopsy N % N % N % <0.001
8 623 72.4 339 64.2 284 85.5
≥9 237 27.6 189 35.8 48 14.5
FU duration after RP, months 51 26–78 44 25–71 59 32–83 0.317




P valueN = 860 N = 528 (61.4%) N = 332 (38.6%)
Median IQR Median IQR Median IQR
Pathologic Features after Radical Prostatectomy
Gleason Score according
to Radical Prostatectomy N % N % N %
6 19 2.2 - 19 5.7
7 (3 + 4) 130 15.1 - 130 39.2
7 (4 + 3) 183 21.2 - 183 55.1
8 219 25.5 219 41.5 -
≥9 309 35.9 309 58.6 -
Pathologic T Stage according
to Radical Prostatectomy N % N % N % <0.001
T2 260 30.2 118 22.3 142 42.8
T3a 348 40.5 208 39.4 140 42.2
≥T3b 252 29.3 202 38.3 50 15.1
ECE 570 66.7 394 74.6 180 54.2 <0.001
SVI 214 24.9 164 31.1 50 15.1 <0.001
PSM 452 52.6 300 56.8 152 45.8 0.002
LVI 11 12.7 84 15.9 25 7.5 <0.001
PNI 629 73.1 405 76.7 224 67.5 0.003
HGPIN 371 43.1 204 38.6 167 50.3 0.001
BCR 502 58.4 360 68.2 142 42.8 <0.001
IQR, interquartile range; BMI, body mass index; PSA, prostate-specific antigen; MRI, magnetic resonance imaging;
RP, radical prostatectomy; ECE, extracapsular extension; SVI, seminal vesicle invasion; PSM, positive surgical
margin; LVI, lymphovascular invasion; PNI, perineural invasion; HGPIN, high-grade prostatic intraepithelial
neoplasia; BCR, biochemical recurrence.
3.2. Preoperative Factors Related to Pathologic Gleason Score (GS) Downgrade (pGS ≤ 7)
In this study, we used univariate and multivariate logistic regression analyses to identify
preoperative predictors of pathologic GS downgrade. Preoperative PSA ≥ 10 ng/mL (odds ratio (OR):
0.606, 95% confidence interval (CI): 0.438–0.840, p = 0.003), bGS ≥ 9 (OR: 0.303, 95% CI: 0.213–0.432,
p < 0.001), and ≥cT3b on mpMRI (OR: 0.284, 95% CI: 0.176–0.458, p < 0.001) were found to be
independent predictors of pathologic GS downgrade at RP in both univariate and multivariate models
(Table 2). Also, in relate of pathologic downgrade, the area under the curves of the receiver operating
characteristic curve was 0.614 (95% CI: 0.575–0.653) in patients with bGS 8, PSA level < 10 ng/mL,
and ≤cT3a.
Table 2. Univariate and multivariate analyses of factors associated with pathologic Gleason score
downgrade in patients with biopsy Gleason scores 8–10.
Variable
Univariate Multivariate
OR (95% CI) p Value OR (95% CI) p Value
Age, year 0.995 (0.975–1.015) 0.592
BMI, kg/m2 1.013 (0.964–1.064) 0.607
Prostate volume, mL 0.996 (0.986–1.005) 0.367
PSA level, ng/mL
<10 1 (Ref) 1 (Ref)
≥10 0.476 (0.359–0.630) <0.001 0.606 (0.438–0.840) 0.003
PSA density 0.679 (0.540–0.854) 0.001 0.973 (0.799–1.185) 0.783
Gleason score
8 1 (Ref) 1 (Ref)
≥9 0.303 (0.213–0.432) <0.001 0.342 (0.238–0.493) <0.001
Clinical stage according to MRI
cT2 1 (Ref) 1 (Ref)
cT3a 0.743 (0.547–1.008) 0.056 0.816 (0.592–1.123) 0.211
≥cT3b 0.219 (0.139–0.346) <0.001 0.284 (0.176–0.458) <0.001
OR, odds ratio; CI, confidence interval; Ref, reference value; BMI, body mass index; PSA, prostate-specific antigen;
MRI, magnetic resonance imaging.
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3.3. Supplementary Analysis of 3-2 (646 Cases)
We analyzed the presence of low-grade PCa core in the biopsy specimens in patients with bGS≥ 8.
In total of 646 cases, we were able to analyze all 12 biopsy cores, including the highest GS. Among
the positive biopsy cores, the patients containing Low GS (bGS < 8) was 356 cases of them. In our
result, presence of low GS core in biopsy was statistically significant with pathologic downgrade.
(OR 3.967, 95% Cl: 2.698–5.833, p < 0.001). In addition, we analyzed according to the lowest GS in
biopsy. The cases including bGS6 were OR 4.926, 95% CI: 3.119–7.779, p < 0.001. The cases including
bGS7 (3 + 4) were OR 4.299, 95% CI: 2.566–7.204, p < 0.001. And the cases including bGS7 (4 + 3) were
OR 2.259, 95% CI: 0.176–0.458, p = 0.006.
3.4. Oncologic Outcomes and Prognostic Factors
During the follow-up period, 502 cases (58.4%) of BCR were noted. Univariate and multivariate
Cox regression analyses were performed with each clinical parameter for BCR. In these analyses,
preoperative PSA (hazard ratio [HR]: 1.005, p = 0.003), PSA ≥10 ng/mL (HR: 1.53, p < 0.001), bGS ≥9
(HR: 1.233, p = 0.042), pGS (pGS ≤7 vs. pGS 8: HR: 1.699, p < 0.001 and vs. pGS ≥9: HR: 1.765,
p < 0.001), SVI (HR: 1.820, p < 0.001), and PSM (HR: 1.819, p < 0.001) were all independent prognostic
factors for BCR (Table 3).
Table 3. Univariate and multivariate analyses of factors associated with biochemical recurrence.
Variable
Univariate Multivariate
HR (95% CI) p Value HR (95% CI) p Value
Age, year 1.005 (0.992–1.018) 0.469
BMI, kg/m2 1.014 (0.982–1.046) 0.399
Prostate volume, ml 1.003 (0.997–1.008) 0.363
PSA, ng/ml 1.006 (1.005–1.008) <0.001 1.005 (1.002–1.009) 0.003
<10 1 (Ref) 1 (Ref)
≥10 2.341 (1.956–2.803) <0.001 1.539 (1.260–1.880) <0.001
PSA density, ng/mL2 1.186 (1.127–1.249) <0.001 0.888 (0.780–1.011) 0.073
Biopsy Gleason score (bGS)
8 1 (Ref) 1 (Ref)
≥9 1.784 (1.485–2.143) <0.001 1.233 (1.008–1.508) 0.042
Pathologic Gleason score (pGS)
≤7 (pGS_downgrade) 1 (Ref) 1 (Ref)
8 1.735 (1.366–2.204) <0.001 1.699 (1.328–2.175) <0.001
≥9 2.810 (2.272–3.474) <0.001 1.765 (1.396–2.231) <0.001
Pathologic T stage
≤T2 1 (Ref) 1 (Ref)
≥T3 5.044 (3.910–6.508) <0.001 1.409 (0.788–2.520) 0.247
ECE
No 1 (Ref) 1 (Ref)
Yes 2.641 (2.122–3.286) <0.001 1.016 (0.594–1.737) 0.955
SVI
No 1 (Ref) 1 (Ref)
Yes 3.139 (2.598–3.792) <0.001 1.820 (1.473–2.249) <0.001
PSM
No 1 (Ref) 1 (Ref)
Yes 2.775 (2.298–3.351) <0.001 1.819 (1.476–2.242) <0.001
LVI
No 1 (Ref) 1 (Ref)
Yes 2.069 (1.639–2.612) <0.001 1.260 (0.987–1.608) 0.063
PNI
No 1 (Ref) 1 (Ref)
Yes 2.013 (1.612–2.512) <0.001 1.244 (0.979–1.580) 0.074
HGPIN
No 1 (Ref)
Yes 0.870 (0.728–1.040) 0.126
HR, hazard ratio; CI, confidence interval; Ref, reference value; BMI, body mass index; PSA, prostate-specific
antigen; ECE, extracapsular extension; SVI, seminal vesicle invasion; PSM, positive surgical margins;
LVI, lymphovascular invasion; PNI, perineural invasion; HGPIN, high-grade prostatic intraepithelial neoplasia;
BCR, biochemical recurrence.
J. Clin. Med. 2019, 8, 438 6 of 10
Analysis according to bGS and pGS using Kaplan–Meier curves was also conduced. In the pGS
downgrade group, the Kaplan–Meier curve showed significantly better BCR-free survival than that
in the other group (log-rank test, p < 0.001). The 5-year BCR-free survival rates was higher in the
pGS downgrade group than that in the other group (50.9% vs. 23.8%). Also, patients with bGS 8,
PSA < 10 ng/mL, and ≤ cT3a showed significantly better 5-year BCR-free survival than the other
patients (55.1% vs. 23.4%, p < 0.001; Figures 1 and 2).
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The patients were then divided into four groups as follows for further analysis: group 1 comprised
patients with bGS 8 and pGS < 7; group 2, patients with bGS ≥ 9 and pGS < 7; group 3, patients with
bGS ≥ 9 and pGS ≥ 8; and group 4, patients with bGS ≥ 9 and pGS ≥ 8. The 5-year BCR-free survival
rates for groups 1, 2, 3, and 4 were 52.9%, 40.7%, 27.2%, and 16.9%, respectively. The hazard ratios of
groups 2, 3, and 4 compared to group 1 were 2.109 (p = 0.146), 38.643 (p < 0.001), and 96.262 (p < 0.001),
respectively. The BCR-free survival curves of the four groups are shown in Figure 3.
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4. Discussion
Since the introduction of the Gleason Grading System [7], bGS 8 or higher has been consistently
classified as high risk and as a predictor of poor oncologic outcome. Patients with bGS 8 are classified
to have high-grade prostate cancer (poorly differentiated prostate cancer). Since the 2005 update
in the Gleason grading system [8], the correlation between bGS and RP GS has improved [19–21].
Major changes in the Gleason system have also been made during the 2014 ISUP [9], and this further
improves the association between bGS and pGS [22]. However, some cases of discordant bGS and
pGS are still reported. Among patients with PCa, those with GS > 8, PSA > 20 ng/mL, or cT3a are
considered to be high risk. Although RP is a treatment option in these patients, combined EBRTx and
ADT are proposed as the first choice of treatment in the National Comprehensive Cancer Network
(NCCN) guideline [10]. The European Association of Urology (EAU) guideline also recommends RP
for selected patients [4], and both the EAU and NCCN guidelines recommend RP in select high-risk
patients. Therefore, in this study, we investigated the favorable indicators for surgical treatment in
patients with high-risk PCa.
pGS downgrade is a well-known favorable prognostic factor, and Donohue et al. [14] reported
that patients with high bGS who have pGS downgrade have good prognosis. In their study, cT1c and
bGS 8 were identified to be predictors of pGS downgrade, which is similar to our results. However,
there were differences about the influence of PSA and clinical stage between the study of Donohue et al.
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and our study. In our study, PSA was set as a criterion for easy patient and used a PSA value of
10 ng/mL as cut-off for low-risk malignancy based on the current standard [10]. Thus, PSA <10 ng/mL
was evaluated as a predictor for downgrade in patients with high-grade PCa on biopsy findings.
In addition, recent developments in mpMRI have improved the image evaluation techniques for ECE
and SVI [23,24]. The clinical stage was evaluated using 3T MRI, which enabled us to distinguish
between T3a and T3b. Thus, the probability of discordance (i.e., pathologic downgrade) in patients
with T3b or higher was minimized. In addition, we found that bGS8, PSA < 10 ng/mL, and ≤ cT3a
were significantly correlated with BCR in patients with high bGS. These factors were also predictors
of pathologic downgrade. The Kaplan–Meier curves of the patients with pathologic downgrade and
those with bGS8, PSA < 10 ng/mL, and ≤ cT3a were similar in this study.
Collectively, these results indicate that patients with high-grade PCa who have PSA < 10 ng/mL,
bGS 8, and ≤ cT3a may have favorable oncological outcomes via RP. This information would be
valuable in providing an indication for surgical treatment in patients with high-grade PCa. In addition,
we believe that bGS remains a crucial factor for determining the appropriate treatment and follow-up
strategy for high-grade PCa.
The oncologic outcome has been reported to differ according to bGS among those with similar
pGS [11,22]. In our study, we also found that BCR-free survival decreased as bGS increased among
those with similar pGS. This suggests that although pGS downgrades may be observed in patients
with high-grade PCa on biopsy, these patients require a more aggressive management after RP than
those with low-grade PCa.
Our study has several limitations. First, this was a retrospective review of data from patients
treated at a single institution. Thus, our results are subject to selection bias, limiting generalizability.
Therefore, multi-center, prospective studies are needed. Second, mpMRI findings have been recently
read based on the Prostate Imaging Reporting and Data System (PI-RADS) [25,26]. However, until 2009
we did not include diffusion-weighted imaging and the apparent-diffusion coefficient in the mpMRI
protocol. Therefore, it was difficult to perform a complete PI-RADS scoring. Recently, PI-RADS scoring
has been reported to be associated with GS [27,28], and this requires further analysis. Third, given
the referral nature of our tertiary center, many men underwent biopsy at outside hospitals. While
all biopsy slides were re-examined by a single experienced group of urological pathologists at our
institute, biopsy data were lacking in some cases, such as the number of positive cores, percentage of
cancer per core, and perineural invasion. In our study, the presence of low GS (bGS <8) core in positive
biopsy cores and pathologic downgrade were statistically significant. Unfortunately, as mentioned
earlier, biopsy data were lacking in some cases. Therefore, it was difficult to analysis the average cancer
portion for all biopsy cores. We think that this analysis may be a good study to reduce the discordance
of biopsy and final GS. However, as a tertiary center, we were able to accommodate many patients
with high-grade PCa. Therefore, a large number of patients were included in this study. In addition, in
the era of mpMRI, the index core via mpMRI fusion biopsy could be one factor that could reduce GS
discrepancies between biopsy and RP specimen. Unfortunately, this was not included in our current
study. Therefore, we believe that further research on this content is necessary.
Despite these limitations, our study is still valuable in that it demonstrates that bGS 8,
PSA < 10 ng/mL, and < cT3b were independent predictors of downgrading GS after RP in patients
with high-grade PCa. In addition, these factors were determined to be predictors of favorable
oncological outcome in these patients. Our findings provide a guide for predicting disease prognosis
and subsequent treatment planning in patients with high-grade PCa.
5. Conclusions
Among patients with high-risk PCa (i.e., those with bGS ≥ 8), those with bGS 8, PSA < 10 ng/mL,
and without SVI on mpMRI may have pGS downgrade and favorable oncologic outcomes. These
patients have fewer adverse pathologic features and can thus benefit from RP in terms of oncologic
prognosis. Therefore, we suggest active treatment such as RP in these patients.
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